Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Di Bartolomeo, P. Di"'
Background: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::60a64e8be607a2d94110070c4a87c17f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3122238
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3122238
Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::e08da6ab5fcd2f814b962746b0506cff
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3004786
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3004786
Autor:
Palka, G., Lawler, M., Morizio, E., Gardiner, N., Stuppia, L., De Arce, M. A., Di Bartolomeo, P. Di, Capodiferro, F., Sabatino, G., Gatta, V., Calabrese, G., Cann, S. R. Mc
Publikováno v:
Hematology; January 1998, Vol. 3 Issue: 3 p193-203, 11p
Autor:
Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletios, OPTIMISMM trial investigators, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A.
Publikováno v:
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BASE-Bielefeld Academic Search Engine
Lancet Oncology, 20(6), 781-794. Lancet Publishing Group
Richardson, P G, Oriol, A, Beksac, M, Liberati, A M, Galli, M, Schjesvold, F, Lindsay, J, Weisel, K, White, D, Facon, T, San Miguel, J, Sunami, K, O'Gorman, P, Sonneveld, P, Robak, P, Semochkin, S, Schey, S, Yu, X, Doerr, T, Bensmaine, A, Biyukov, T, Peluso, T, Zaki, M, Anderson, K, Dimopoulos, M, OPTIMISMM trial investigators & Abildgaard, N 2019, ' Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 20, no. 6, pp. 781-794 . https://doi.org/10.1016/S1470-2045(19)30152-4
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BASE-Bielefeld Academic Search Engine
Lancet Oncology, 20(6), 781-794. Lancet Publishing Group
Richardson, P G, Oriol, A, Beksac, M, Liberati, A M, Galli, M, Schjesvold, F, Lindsay, J, Weisel, K, White, D, Facon, T, San Miguel, J, Sunami, K, O'Gorman, P, Sonneveld, P, Robak, P, Semochkin, S, Schey, S, Yu, X, Doerr, T, Bensmaine, A, Biyukov, T, Peluso, T, Zaki, M, Anderson, K, Dimopoulos, M, OPTIMISMM trial investigators & Abildgaard, N 2019, ' Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 20, no. 6, pp. 781-794 . https://doi.org/10.1016/S1470-2045(19)30152-4
Background As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cccf2220a5bc187bbb4a4254d3d0f52
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4189
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4189